DRD3 Gene and ADHD: A Pharmaco-Behavioural Genetic Study

Overview

Journal Neuromolecular Med

Specialty Biochemistry

Date 2018 Jul 28

PMID 30051166

Citations 6

Authors

Weam Fageera

Sarojini M Sengupta

Aurelie Labbe

Natalie Grizenko

Ridha Joober

Affiliations

Soon will be listed here.

Abstract

Results of candidate gene investigations in ADHD have been difficult to replicate. The complexity of the phenotypes and their underlying determinants, and the relatively small effect sizes of genetic variants may, in part, be contributing to these inconsistencies. The objective of this study is to conduct an exploratory analysis using a comprehensive approach to investigate the role of candidate genes. This approach combines a dimensional behavioural approach akin to Research Domain Criteria (RDoC), a pharmaco-dynamic evaluation of behaviours relevant to ADHD, together with association and linkage testing in a large sample of children with ADHD. Parents, teachers, and research staff evaluated children with ADHD under three experimental conditions (EC): 1 week of baseline observation, followed by 1 week of methylphenidate (MPH) and 1 week of placebo, administered in a double-blind crossover order. Several quantitative behavioural and cognitive dimensions relevant for ADHD were also assessed. We combined family-based (FBAT) and quantitative trait genetic analyses (n = 575 probands with members of their nuclear families) to investigate the role of DRD3 (Ser-9-Gly) in ADHD and its relevant behavioural dimensions. Comparing the behaviours of children with different genotypes under the three EC showed a nominal association between the T allele and poorer behavioural scores during the MPH week (as assessed by teachers), particularly in boys. With the family-based analysis, the T allele showed a nominal association with increased risk for ADHD, response to placebo and MPH as assessed by research staff, and the modulation of other behavioural and cognitive dimensions. These results provide convergent, albeit preliminary evidence for the implication of the DRD3 (Ser-9-Gly) polymorphism in the aetiology of ADHD and the modulation of its various behavioural dimensions, including RDoC cognitive constructs and response to pharmacological probes. This illustrative example suggests that this research paradigm might help to reliably uncover the role of other candidate genes in ADHD.

Citing Articles

Gene-gene and gene-environmental interaction of dopaminergic system genes in Pakistani children with attention deficit hyperactivity disorder.

Ansari M, Naqvi H, Khidri F, Rajput A, Mahmood A, Waryah A Saudi J Biol Sci. 2024; 31(8):104045.

PMID: 39050560 PMC: 11268355. DOI: 10.1016/j.sjbs.2024.104045.

The Impact of Genetics on Cognition: Insights into Cognitive Disorders and Single Nucleotide Polymorphisms.

Spoto G, Di Rosa G, Nicotera A J Pers Med. 2024; 14(2).

PMID: 38392589 PMC: 10889941. DOI: 10.3390/jpm14020156.

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Storebo O, Storm M, Ribeiro J, Skoog M, Groth C, Callesen H Cochrane Database Syst Rev. 2023; 3:CD009885.

PMID: 36971690 PMC: 10042435. DOI: 10.1002/14651858.CD009885.pub3.

Facing the Methodological Challenge in Dissecting the Genetics of ADHD: A Case for Deep Phenotyping and Heterogeneity Reduction.

Sengupta S, Grizenko N, Fortier M, Ter-Stepanian M, Joober R J Can Acad Child Adolesc Psychiatry. 2020; 29(3):188-201.

PMID: 32774401 PMC: 7391869.

No association between the Ser9Gly polymorphism of the dopamine receptor D3 gene and schizophrenia: a meta-analysis of family-based association studies.

Li X, Zheng J, Wei X, Wang B, Yao J BMC Med Genet. 2020; 21(1):85.

PMID: 32316934 PMC: 7171831. DOI: 10.1186/s12881-020-01018-w.

References

Mizrahi R, Addington J, Rusjan P, Suridjan I, Ng A, Boileau I . Increased stress-induced dopamine release in psychosis. Biol Psychiatry. 2011; 71(6):561-7. DOI: 10.1016/j.biopsych.2011.10.009. View

Svensson K, Carlsson A, Waters N . Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect. 1994; 95(1):71-4. DOI: 10.1007/BF01283032. View

Payton A, Holmes J, Barrett J, Hever T, FITZPATRICK H, Trumper A . Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder: a family-based study. Am J Med Genet. 2001; 105(5):464-70. DOI: 10.1002/ajmg.1407. View

Garvey M, Avenevoli S, Anderson K . The National Institute of Mental Health Research Domain Criteria and Clinical Research in Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 2016; 55(2):93-8. PMC: 4724376. DOI: 10.1016/j.jaac.2015.11.002. View

Joshua M, Adler A, Bergman H . The dynamics of dopamine in control of motor behavior. Curr Opin Neurobiol. 2009; 19(6):615-20. DOI: 10.1016/j.conb.2009.10.001. View

Schultz W . Dopamine signals for reward value and risk: basic and recent data. Behav Brain Funct. 2010; 6:24. PMC: 2876988. DOI: 10.1186/1744-9081-6-24. View

Haldar T, Ghosh S . Power comparison between population-based case-control studies and family-based transmission-disequilibrium tests: An empirical study. Indian J Hum Genet. 2011; 17 Suppl 1:S27-31. PMC: 3125051. DOI: 10.4103/0971-6866.80355. View

Horvath S, Xu X, Laird N . The family based association test method: strategies for studying general genotype--phenotype associations. Eur J Hum Genet. 2001; 9(4):301-6. DOI: 10.1038/sj.ejhg.5200625. View

Wilens T . Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008; 28(3 Suppl 2):S46-53. DOI: 10.1097/JCP.0b013e318173312f. View

10.

Baroni A, Castellanos F . Neuroanatomic and cognitive abnormalities in attention-deficit/hyperactivity disorder in the era of 'high definition' neuroimaging. Curr Opin Neurobiol. 2014; 30:1-8. PMC: 4293331. DOI: 10.1016/j.conb.2014.08.005. View

11.

Murray D, Stoessl A . Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. Pharmacol Ther. 2013; 140(3):306-18. DOI: 10.1016/j.pharmthera.2013.07.009. View

12.

Barr C, Wigg K, Wu J, Zai C, Bloom S, Tannock R . Linkage study of two polymorphisms at the dopamine D3 receptor gene and attention-deficit hyperactivity disorder. Am J Med Genet. 2000; 96(1):114-7. View

13.

Schultz W . Dopamine reward prediction-error signalling: a two-component response. Nat Rev Neurosci. 2016; 17(3):183-95. PMC: 5549862. DOI: 10.1038/nrn.2015.26. View

14.

Polanczyk G, Willcutt E, Salum G, Kieling C, Rohde L . ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014; 43(2):434-42. PMC: 4817588. DOI: 10.1093/ije/dyt261. View

15.

Shaffer D, Fisher P, Lucas C, Dulcan M . NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry. 2000; 39(1):28-38. DOI: 10.1097/00004583-200001000-00014. View

16.

de la Fuente-Fernandez R, Lidstone S, Stoessl A . Placebo effect and dopamine release. J Neural Transm Suppl. 2006; (70):415-8. DOI: 10.1007/978-3-211-45295-0_62. View

17.

Barkley R . Differential diagnosis of adults with ADHD: the role of executive function and self-regulation. J Clin Psychiatry. 2010; 71(7):e17. DOI: 10.4088/JCP.9066tx1c. View

18.

Willcutt E, Doyle A, Nigg J, Faraone S, Pennington B . Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005; 57(11):1336-46. DOI: 10.1016/j.biopsych.2005.02.006. View

19.

Wu J, Xiao H, Sun H, Zou L, Zhu L . Role of dopamine receptors in ADHD: a systematic meta-analysis. Mol Neurobiol. 2012; 45(3):605-20. DOI: 10.1007/s12035-012-8278-5. View

20.

Daly S, Waddington J . Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology. 1993; 32(5):509-10. DOI: 10.1016/0028-3908(93)90177-5. View